Skip to main content
RLAYRelay Therapeutics, Inc.Sell4.4·$17.99

Relay Therapeutics (RLAY) Q3 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+7.8% vs estimateEPS -$0.37 vs -$0.40 estCurrent verdict Sell 4.4/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.37
Estimate
-$0.40
Surprise
+7.8%
Score today
4.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q3 2026

How the report landed

Relay Therapeutics (RLAY) reported a narrower loss than forecast — adjusted EPS of -$0.37 against the -$0.40 estimate (a 7.8% beat on a still-unprofitable quarter).

Around the report

Coverage in the report window

  • Relay Therapeutics Reports Q3 2026 Financial Results — fiscal.ai, 2026-11-04
  • Relay Therapeutics Q3 EPS $(0.37) Beats $(0.40) Estimate — benzinga, 2026-11-04
  • Lirafugratinib (Lyrfigtu™) Added to NCCN Clinical Practice Guidelines — fiscal.ai, 2026-11-03
Current read · as of 2026-11-06

Where TrendMatrix's rating stands now

TrendMatrix currently rates RLAY Sell at 4.4/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +7.8% surprise compares with a +2.4% four-quarter average. Next scheduled report: 2027-02-25.

What argues against it

  • Concentration risk — Pipeline: zovegalisib (RLY-2608)
  • Quality below floor (1.5 < 4.0)
  • Value-trap signals (3/5): Margin compression (op margin -42.6%), Material insider selling (20 sells, 0.40% of cap), Negative free cash flow

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$17.99
Price target
$24.00
Stop
$16.73
Upside to target
+33.4%
Reward-to-risk
2.7:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare context

RLAY at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$3.73B
P/E (fwd)
-10.4
52-week range
$5.95–$21.27
Off 52-week high
15.4%
RSI (14)
55
Volume vs avg
0.29×
Score today
4.4/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › RLAY › Earnings › Q3 2026 earnings